Paul J. Diaz

Paul J. Diaz

President and Chief Executive OfficeratMyriad Genetics· In proxies 2022–2024

Pay in FY2024+13% from the year before · Myriad Genetics stock -28.4% the same year

Paul J. Diaz was paid $13.6M in FY2024 (Dec), up 13%. Myriad Genetics stock fell 28.4% that year.

Pay$100 in the stock at the end of FY21 → $50
Pay is from the Summary Compensation Table of each Myriad Genetics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Myriad GeneticsPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -76%
  2. DavitaPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Johns Hopkins Health PlansPublic company
    • Director? – PresentNo stock prices for these years
  4. Johns Hopkins MedicinePublic company
    • Director? – PresentNo stock prices for these years
  5. Federation of American HospitalsPublic company
    • Director? – PresentNo stock prices for these years
  6. PharMerica CorporationPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Myriad GeneticsDirector · 4 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?